Fecal microbiota transplantation for gastrointestinal diseases

Katsuyoshi Matsuoka, Shinta Mizuno, Atsushi Hayashi, Tadakazu Hisamatsu, Makoto Naganuma, Takanori Kanai

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Fecal microbiota transplantation (FMT) is a treatment to restore the normal microbial composition of the gut by introducing fecal microbiota obtained from a healthy donor into a diseased individual. There has been a growing interest in the use of FMT as a treatment of various diseases including Clostridium difficile infection (CDI), inflammatory bowel disease, and irritable bowel syndrome. Despite the increasing application of FMT, there are no standard protocols. Many aspects of FMT procedures vary regarding donor selection, preparation of fecal materials, recipient preparation, and route of administration. FMT is most successful in treating recurrent CDI. A randomized controlled trial reported a success rate of approximaetly 90%. Ulcerative colitis (UC) is a potentially good indication for FMT, although limited evidence is available on the use of FMT for the treatment of UC. Only several small case series have been reported, and the results in terms of efficacy are inconsistent. FMT can also be used to treat diseases other than gastrointestinal disorders in which the gut microbiota is disturbed, e.g., cardiovascular diseases, autoimmune diseases, and metabolic disorders. There remain many unanswered questions with regard to FMT, and more research is required in this field.

Original languageEnglish
Pages (from-to)69-74
Number of pages6
JournalKeio Journal of Medicine
Volume63
Issue number4
DOIs
Publication statusPublished - 2014 Dec 1

Fingerprint

Gastrointestinal Diseases
Clostridium Infections
Clostridium difficile
Ulcerative Colitis
Fecal Microbiota Transplantation
Donor Selection
Irritable Bowel Syndrome
Microbiota
Inflammatory Bowel Diseases
Autoimmune Diseases
Cardiovascular Diseases
Therapeutics
Randomized Controlled Trials

Keywords

  • Clostridium difficile
  • Crohn’s disease
  • Gut microbiota
  • Transplantation
  • Ulcerative colitis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Fecal microbiota transplantation for gastrointestinal diseases. / Matsuoka, Katsuyoshi; Mizuno, Shinta; Hayashi, Atsushi; Hisamatsu, Tadakazu; Naganuma, Makoto; Kanai, Takanori.

In: Keio Journal of Medicine, Vol. 63, No. 4, 01.12.2014, p. 69-74.

Research output: Contribution to journalArticle

Matsuoka, Katsuyoshi ; Mizuno, Shinta ; Hayashi, Atsushi ; Hisamatsu, Tadakazu ; Naganuma, Makoto ; Kanai, Takanori. / Fecal microbiota transplantation for gastrointestinal diseases. In: Keio Journal of Medicine. 2014 ; Vol. 63, No. 4. pp. 69-74.
@article{af247f1cd8b045e0a0ff9a33220e8706,
title = "Fecal microbiota transplantation for gastrointestinal diseases",
abstract = "Fecal microbiota transplantation (FMT) is a treatment to restore the normal microbial composition of the gut by introducing fecal microbiota obtained from a healthy donor into a diseased individual. There has been a growing interest in the use of FMT as a treatment of various diseases including Clostridium difficile infection (CDI), inflammatory bowel disease, and irritable bowel syndrome. Despite the increasing application of FMT, there are no standard protocols. Many aspects of FMT procedures vary regarding donor selection, preparation of fecal materials, recipient preparation, and route of administration. FMT is most successful in treating recurrent CDI. A randomized controlled trial reported a success rate of approximaetly 90{\%}. Ulcerative colitis (UC) is a potentially good indication for FMT, although limited evidence is available on the use of FMT for the treatment of UC. Only several small case series have been reported, and the results in terms of efficacy are inconsistent. FMT can also be used to treat diseases other than gastrointestinal disorders in which the gut microbiota is disturbed, e.g., cardiovascular diseases, autoimmune diseases, and metabolic disorders. There remain many unanswered questions with regard to FMT, and more research is required in this field.",
keywords = "Clostridium difficile, Crohn’s disease, Gut microbiota, Transplantation, Ulcerative colitis",
author = "Katsuyoshi Matsuoka and Shinta Mizuno and Atsushi Hayashi and Tadakazu Hisamatsu and Makoto Naganuma and Takanori Kanai",
year = "2014",
month = "12",
day = "1",
doi = "10.2302/kjm.2014-0006-RE",
language = "English",
volume = "63",
pages = "69--74",
journal = "Keio Journal of Medicine",
issn = "0022-9717",
publisher = "Keio University School of Medicine",
number = "4",

}

TY - JOUR

T1 - Fecal microbiota transplantation for gastrointestinal diseases

AU - Matsuoka, Katsuyoshi

AU - Mizuno, Shinta

AU - Hayashi, Atsushi

AU - Hisamatsu, Tadakazu

AU - Naganuma, Makoto

AU - Kanai, Takanori

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Fecal microbiota transplantation (FMT) is a treatment to restore the normal microbial composition of the gut by introducing fecal microbiota obtained from a healthy donor into a diseased individual. There has been a growing interest in the use of FMT as a treatment of various diseases including Clostridium difficile infection (CDI), inflammatory bowel disease, and irritable bowel syndrome. Despite the increasing application of FMT, there are no standard protocols. Many aspects of FMT procedures vary regarding donor selection, preparation of fecal materials, recipient preparation, and route of administration. FMT is most successful in treating recurrent CDI. A randomized controlled trial reported a success rate of approximaetly 90%. Ulcerative colitis (UC) is a potentially good indication for FMT, although limited evidence is available on the use of FMT for the treatment of UC. Only several small case series have been reported, and the results in terms of efficacy are inconsistent. FMT can also be used to treat diseases other than gastrointestinal disorders in which the gut microbiota is disturbed, e.g., cardiovascular diseases, autoimmune diseases, and metabolic disorders. There remain many unanswered questions with regard to FMT, and more research is required in this field.

AB - Fecal microbiota transplantation (FMT) is a treatment to restore the normal microbial composition of the gut by introducing fecal microbiota obtained from a healthy donor into a diseased individual. There has been a growing interest in the use of FMT as a treatment of various diseases including Clostridium difficile infection (CDI), inflammatory bowel disease, and irritable bowel syndrome. Despite the increasing application of FMT, there are no standard protocols. Many aspects of FMT procedures vary regarding donor selection, preparation of fecal materials, recipient preparation, and route of administration. FMT is most successful in treating recurrent CDI. A randomized controlled trial reported a success rate of approximaetly 90%. Ulcerative colitis (UC) is a potentially good indication for FMT, although limited evidence is available on the use of FMT for the treatment of UC. Only several small case series have been reported, and the results in terms of efficacy are inconsistent. FMT can also be used to treat diseases other than gastrointestinal disorders in which the gut microbiota is disturbed, e.g., cardiovascular diseases, autoimmune diseases, and metabolic disorders. There remain many unanswered questions with regard to FMT, and more research is required in this field.

KW - Clostridium difficile

KW - Crohn’s disease

KW - Gut microbiota

KW - Transplantation

KW - Ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=84920541630&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920541630&partnerID=8YFLogxK

U2 - 10.2302/kjm.2014-0006-RE

DO - 10.2302/kjm.2014-0006-RE

M3 - Article

C2 - 25500625

AN - SCOPUS:84920541630

VL - 63

SP - 69

EP - 74

JO - Keio Journal of Medicine

JF - Keio Journal of Medicine

SN - 0022-9717

IS - 4

ER -